Who are Pfizer's decision-makers?
Pfizer is led by Albert Bourla. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Albert Bourla
- CFO/key exec
- David Denton
- Founded
- 1849
- Employees
- 81,000+
- HQ
- New York, NY
- Status
- NYSE: PFE
- Albert BourlaChairman and Chief Executive OfficerCEO since 2019Leads Pfizer through post-COVID portfolio repositioning and oncology expansion.
- David DentonChief Financial Officer and Executive Vice PresidentCFO since 2022Oversees capital allocation, margin programs, and financial planning.
- Chris BoshoffChief Scientific Officer and President, Research and DevelopmentCSO in 2026Runs R&D strategy across oncology, immunology, vaccines, and internal medicine.
- Aamir MalikChief U.S. Commercial Officer and Executive Vice PresidentCommercial leader in 2026Leads U.S. commercialization and market access execution.
Who leads Pfizer?
Pfizer's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Pfizer?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Pfizer organized as it scales?
Pfizer operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Pfizer leadershipPfizer annual reports
Pfizer — frequently asked questions
